Compare ARK Genomic Revolution ETF (ARKG) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Goldman Sachs Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Goldman Sachs Group Inc trades at $1,061.94 (market cap $311.29B). The key difference: Goldman Sachs Group Inc pays a 1.71% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | GS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $1.11K |
52-Week Low | $23.09 | $700.41 |
Market Cap | — | $311.29B |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Goldman Sachs (GS) trades at $1,055.18, down 0.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $17.55 surpassing expectations of $16.47. Revenue grew to $58.28 billion in 2025, and net income margin improved to 29.89%. Recent news highlights GS's role in leading high-profile IPOs like Anthropic, signaling robust investment banking activity. The stock is near its pivot point of $1,055, with support at $1,045 and resistance at $1,065.
The outlook for GS is positive, driven by earnings momentum and a favorable IPO pipeline, but risks include volatile cash flows and macroeconomic sensitivity. Analyst consensus is a Buy with a price target of $1,080, indicating potential upside. Investors should monitor execution in investment banking and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
